Peptide Research Information

Mechanism of action, research history, notable studies, and common research protocols for each peptide. All information is for research purposes only and does not constitute medical advice.

Research purposes only. This information does not constitute medical advice. Always consult a qualified healthcare professional before considering any substance for personal use.

BPC-157

Body Protection Compound 157, Pentadecapeptide BPC 157

A stable 15-amino acid gastric peptide studied for tissue repair and cytoprotection.

Pentadecapeptide / Gastroprotective peptide

1419.56 Da

4 studies2 protocols

TB-500

Thymosin Beta-4, Tβ4

A synthetic form of Thymosin Beta-4, a ubiquitous actin-sequestering protein studied for wound healing and tissue regeneration.

Beta-thymosin / Actin-sequestering peptide

~4,963 Da (44-residue form)

4 studies2 protocols

Semaglutide

Ozempic, Wegovy

A long-acting GLP-1 receptor agonist with established efficacy in type 2 diabetes and obesity clinical trials.

GLP-1 receptor agonist / Incretin mimetic

4,113.58 Da

4 studies2 protocols

Tirzepatide

Mounjaro, Zepbound

The first dual GIP and GLP-1 receptor agonist, demonstrating superior weight loss and glycemic control in large clinical trials.

Dual GIP/GLP-1 receptor agonist / Dual incretin mimetic

4,813.48 Da

4 studies2 protocols

CJC-1295

Modified GRF 1-29, Mod GRF 1-29

A GHRH analog engineered for extended half-life, studied for its ability to stimulate sustained pulsatile growth hormone release.

GHRH analog / Growth hormone secretagogue

~3,367 Da (without DAC) / ~3,647 Da (with DAC)

3 studies2 protocols

Ipamorelin

NNC 26-0161

A highly selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist studied for clean, pulsatile GH release.

Pentapeptide / Growth hormone secretagogue (GHRP)

711.85 Da

3 studies2 protocols

Retatrutide

LY3437943

A synthetic triple agonist activating GIP, GLP-1, and glucagon receptors simultaneously, studied for its multi-pathway effects on weight and metabolic regulation.

Triple hormone receptor agonist (GIP / GLP-1 / glucagon) — synthetic peptide

~4,731 Da (fatty-acid-modified peptide)

3 studies1 protocols

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

A 16-amino-acid, mitochondrial-DNA-encoded peptide studied as an exercise mimetic for its effects on AMPK activation and metabolic homeostasis.

16-amino-acid mitochondrial-derived peptide (MDP) / Metabolic regulator

2,174.59 Da

3 studies2 protocols

GHK-Cu

Copper Tripeptide-1, Gly-His-Lys-Cu(II)

A naturally occurring copper-binding tripeptide studied for its roles in collagen synthesis, tissue remodeling, and antioxidant activity.

Copper-binding tripeptide / Tissue-remodeling and antioxidant peptide

~403 Da (peptide–copper complex)

9 studies1 protocols

AOD-9604

hGH Fragment 176-191, Advanced Obesity Drug 9604

A modified 16-amino-acid fragment of human growth hormone studied for lipolytic effects without the growth-promoting activity of full-length hGH.

Modified 16-amino-acid hGH fragment / Lipolytic peptide

~1,815 Da

3 studies1 protocols

NAD+

Nicotinamide Adenine Dinucleotide

An essential cellular coenzyme and substrate for sirtuins and PARP enzymes, studied for its role in energy metabolism, DNA repair, and its decline with age.

Nucleotide coenzyme (oxidized dinucleotide) — cellular metabolism research compound

663.43 Da

3 studies1 protocols

Tesamorelin

TH9507, Egrifta

A stabilized analog of the full-length growth hormone-releasing factor, GRF(1-44), studied for its ability to reduce visceral fat by restoring the body's own pulsatile growth hormone release.

GHRH analog / Growth hormone-releasing factor (GRF) analog

5,135.9 Da (free base)

3 studies2 protocols

This information is for research purposes only and does not constitute medical advice. Peptides listed here may not be approved for human use in your jurisdiction.